This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leverkus, M. Articles by Walczak, H. Search for Related Content PubMed PubMed Citation Articles by Leverkus, M. Articles by Walczak, H.

Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitivity in Primary and Transformed Human Keratinocytes¹

Departments of Dermatology [M. L., T. M., E-B. B.] and Pathology [M. N.], University of Würzburg Medical School, 97080 Würzburg, Germany; Immunex Corporation, Department of Protein Chemistry, Seattle, Washington 98101 [C. T. R.]; and Deutsches Krebsforschungszentrum Tumor Immunology Program, German Cancer Research Center, 69120 Heidelberg, Germany [P. H. K., H. W.]

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to exert potent cytotoxic activity against many tumor cell lines but not against normal cells. It has been hypothesized that this difference in TRAIL sensitivity between normal and transformed cells might be due to the expression of the non-death-inducing TRAIL receptors (TRAIL-R) TRAIL-R3 and TRAIL-R4, presumably by competition for limited amounts of TRAIL. To assess the regulation of resistance versus sensitivity to TRAIL in primary as well as transformed keratinocytes, we examined TRAIL sensitivity, TRAIL receptor expression, and intracellular signaling events induced by TRAIL. Although TRAIL induced apoptosis in primary as well as transformed keratinocytes, a marked difference in sensitivity could be observed with primary keratinocytes (PK) being 5-fold less sensitive to TRAIL than transformed keratinocytes (TK). Yet both cell types exhibited similar TRAIL receptor surface expression, suggesting that expression of TRAIL-R3 and TRAIL-R4 may not be the main regulator of sensitivity to TRAIL. Biochemical analysis of the signaling events induced by TRAIL revealed that PK could be sensitized for TRAIL and, similarly, for TRAIL-R1- and TRAIL-R2-specific apoptosis by pretreatment of the cells with cycloheximide (CHX). This sensitization concomitantly resulted in processing of caspase-8, which did not occur in TRAIL-resistant PK. These data indicate that an early block of TRAIL-induced apoptosis was present in PK compared with TK or PK treated with CHX. Interestingly, cellular FLICE inhibitory protein (cFLIP) levels, high in PK and low in TK and several other squamous cell carcinoma cell lines, decreased rapidly after treatment of PK with CHX, correlating with the increase in TRAIL sensitivity and caspase-8 processing. Furthermore, ectopic expression of cFLIP long (cFLIP_L) in TK by transfection with a cFLIP_L expression vector resulted in resistance to TRAIL-mediated apoptosis of these cells. Thus, our results demonstrate that TRAIL sensitivity in PK is primarily regulated at the intracellular level rather than at the receptor level.

This article has been cited by other articles:

				S. Kato, A. Sadarangani, S. Lange, A. M. Delpiano, M. Vargas, J. Branes, J. Carvajal, S. Lipkowitz, G. I. Owen, and M. A. Cuello 2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts Reproductive Sciences, November 1, 2008; 15(9): 878 - 894. [Abstract] [PDF]

				S. Rong, J. H. Cai, and J. Andrews Cloning and apoptosis-inducing activities of canine and feline TRAIL Mol. Cancer Ther., July 1, 2008; 7(7): 2181 - 2191. [Abstract] [Full Text] [PDF]

				R. M. Locklin, E. Federici, B. Espina, P. A. Hulley, R. G. G. Russell, and C. M. Edwards Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis Mol. Cancer Ther., December 1, 2007; 6(12): 3219 - 3228. [Abstract] [Full Text] [PDF]

				F. Meslin, A. Hamai, P. Gao, A. Jalil, N. Cahuzac, S. Chouaib, and M. Mehrpour Silencing of Prion Protein Sensitizes Breast Adriamycin-Resistant Carcinoma Cells to TRAIL-Mediated Cell Death Cancer Res., November 15, 2007; 67(22): 10910 - 10919. [Abstract] [Full Text] [PDF]

				G. J. Ullenhag, A. Mukherjee, N. F.S. Watson, A. H. Al-Attar, J. H. Scholefield, and L. G. Durrant Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients Clin. Cancer Res., September 1, 2007; 13(17): 5070 - 5075. [Abstract] [Full Text] [PDF]

				G. Roue, P. Perez-Galan, M. Lopez-Guerra, N. Villamor, E. Campo, and D. Colomer Selective Inhibition of I{kappa}B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level J. Immunol., February 1, 2007; 178(3): 1923 - 1930. [Abstract] [Full Text] [PDF]

				J. Shi, Y. Liu, Y. Zheng, Y. Guo, J. Zhang, P.-t. Cheung, R. Xu, and D. Zheng Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice Cancer Res., December 15, 2006; 66(24): 11946 - 11953. [Abstract] [Full Text] [PDF]

				J. Gong, D. Yang, S. Kohanim, R. Humphreys, L. Broemeling, and R. Kurzrock Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies Mol. Cancer Ther., December 1, 2006; 5(12): 2991 - 3000. [Abstract] [Full Text] [PDF]

				S. J. Braeuer, C. Buneker, A. Mohr, and R. M. Zwacka Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells Mol. Cancer Res., October 1, 2006; 4(10): 715 - 728. [Abstract] [Full Text] [PDF]

				M. Jalving, S. de Jong, J. J. Koornstra, W. Boersma-van Ek, N. Zwart, J. Wesseling, E. G.E. de Vries, and J. H. Kleibeuker TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas. Clin. Cancer Res., July 15, 2006; 12(14): 4350 - 4356. [Abstract] [Full Text] [PDF]

				B Mundt, T Wirth, L Zender, M Waltemathe, C Trautwein, M P Manns, F Kuhnel, and S Kubicka Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake Gut, November 1, 2005; 54(11): 1590 - 1596. [Abstract] [Full Text] [PDF]

				E. Bremer, D. F. Samplonius, M. Peipp, L. van Genne, B.-J. Kroesen, G. H. Fey, M. Gramatzki, L. F.M.H. de Leij, and W. Helfrich Target Cell-Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7 Cancer Res., April 15, 2005; 65(8): 3380 - 3388. [Abstract] [Full Text] [PDF]

				E. Bremer, D. F. Samplonius, L. van Genne, M. H. Dijkstra, B. J. Kroesen, L. F. M. H. de Leij, and W. Helfrich Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR J. Biol. Chem., March 18, 2005; 280(11): 10025 - 10033. [Abstract] [Full Text] [PDF]

				T. Matsuda, A. Almasan, M. Tomita, J.-n. Uchihara, M. Masuda, K. Ohshiro, N. Takasu, H. Yagita, T. Ohta, and N. Mori Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines J. Virol., February 1, 2005; 79(3): 1367 - 1378. [Abstract] [Full Text] [PDF]

				T.-G. Jin, A. Kurakin, N. Benhaga, K. Abe, M. Mohseni, F. Sandra, K. Song, B. K. Kay, and R. Khosravi-Far Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5 J. Biol. Chem., December 31, 2004; 279(53): 55594 - 55601. [Abstract] [Full Text] [PDF]

				T. Wachter, M. Sprick, D. Hausmann, A. Kerstan, K. McPherson, G. Stassi, E.-B. Brocker, H. Walczak, and M. Leverkus cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-{kappa}B Activation at the Death-inducing Signaling Complex in Human Keratinocytes J. Biol. Chem., December 17, 2004; 279(51): 52824 - 52834. [Abstract] [Full Text] [PDF]

				A. Marconi, P. Atzei, C. Panza, C. Fila, R. Tiberio, F. Truzzi, T. Wachter, M. Leverkus, and C. Pincelli FLICE/caspase-8 activation triggers anoikis induced by {beta}1-integrin blockade in human keratinocytes J. Cell Sci., November 15, 2004; 117(24): 5815 - 5823. [Abstract] [Full Text] [PDF]

				J. K. Riley, J. M. Heeley, A. H. Wyman, E. L. Schlichting, and K. H. Moley TRAIL and KILLER Are Expressed and Induce Apoptosis in the Murine Preimplantation Embryo Biol Reprod, September 1, 2004; 71(3): 871 - 877. [Abstract] [Full Text] [PDF]

				S. Kreuz, D. Siegmund, J.-J. Rumpf, D. Samel, M. Leverkus, O. Janssen, G. Hacker, O. Dittrich-Breiholz, M. Kracht, P. Scheurich, et al. NF{kappa}B activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP J. Cell Biol., August 2, 2004; 166(3): 369 - 380. [Abstract] [Full Text] [PDF]

				D. Mezzanzanica, E. Balladore, F. Turatti, E. Luison, P. Alberti, M. Bagnoli, M. Figini, A. Mazzoni, F. Raspagliesi, M. Oggionni, et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma Clin. Cancer Res., August 1, 2004; 10(15): 5202 - 5214. [Abstract] [Full Text] [PDF]

				D. Deeb, H. Jiang, X. Gao, M. S. Hafner, H. Wong, G. Divine, R. A. Chapman, S. A. Dulchavsky, and S. C. Gautam Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-{kappa}B through suppression of I{kappa}B{alpha} phosphorylation Mol. Cancer Ther., July 1, 2004; 3(7): 803 - 812. [Abstract] [Full Text] [PDF]

				W. Matsuyama, M. Yamamoto, I. Higashimoto, K.-i. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus Blood, July 1, 2004; 104(1): 184 - 191. [Abstract] [Full Text] [PDF]

				L. B. Pritzker, M. Scatena, and C. M. Giachelli The Role of Osteoprotegerin and Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Human Microvascular Endothelial Cell Survival Mol. Biol. Cell, June 1, 2004; 15(6): 2834 - 2841. [Abstract] [Full Text] [PDF]

				I. Schmitz, H. Weyd, A. Krueger, S. Baumann, S. C. Fas, P. H. Krammer, and S. Kirchhoff Resistance of Short Term Activated T Cells to CD95-Mediated Apoptosis Correlates with De Novo Protein Synthesis of c-FLIPshort J. Immunol., February 15, 2004; 172(4): 2194 - 2200. [Abstract] [Full Text] [PDF]

				N. Harper, M. A. Hughes, S. N. Farrow, G. M. Cohen, and M. MacFarlane Protein Kinase C Modulates Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Targeting the Apical Events of Death Receptor Signaling J. Biol. Chem., November 7, 2003; 278(45): 44338 - 44347. [Abstract] [Full Text] [PDF]

				A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]

				J. H. Song, D. K. Song, M. Herlyn, K. C. Petruk, and C. Hao Cisplatin Down-Regulation of Cellular Fas-associated Death Domain-like Interleukin-1{beta}-converting Enzyme-like Inhibitory Proteins to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Melanoma Cells Clin. Cancer Res., September 15, 2003; 9(11): 4255 - 4266. [Abstract] [Full Text] [PDF]

				M. Leverkus, A. D. McLellan, M. Heldmann, A. O. Eggert, E.-B. Brocker, N. Koch, and E. Kampgen MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways Int. Immunol., August 1, 2003; 15(8): 993 - 1006. [Abstract] [Full Text] [PDF]

				M. Leverkus, M. R. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E.-B. Brocker, M. Goebeler, M. Neumann, and H. Walczak Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation Mol. Cell. Biol., February 1, 2003; 23(3): 777 - 790. [Abstract] [Full Text]

				C. W. Xiao, X. Yan, Y. Li, S. A. G. Reddy, and B. K. Tsang Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor {alpha} Is a Consequence of Nuclear Factor {kappa}B-Mediated Induction of Fas-Associated Death Domain-Like Interleukin-1{beta}-Converting Enzyme-Like Inhibitory Protein Endocrinology, February 1, 2003; 144(2): 623 - 630. [Abstract] [Full Text] [PDF]

				J. Ursini-Siegel, W. Zhang, A. Altmeyer, E. N. Hatada, R. K. G. Do, H. Yagita, and S. Chen-Kiang TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis J. Immunol., November 15, 2002; 169(10): 5505 - 5513. [Abstract] [Full Text] [PDF]

				M. A. Eid, R. W. Lewis, and M. V. Kumar Mifepristone Pretreatment Overcomes Resistance of Prostate Cancer Cells to Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand (TRAIL) Mol. Cancer Ther., August 1, 2002; 1(10): 831 - 840. [Abstract] [Full Text] [PDF]

				G. Dorothee, I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-{alpha} on APO2L/TRAIL Expression and -Mediated Cytotoxicity J. Immunol., July 15, 2002; 169(2): 809 - 817. [Abstract] [Full Text] [PDF]

				T. S. Griffith, J. M. Fialkov, D. L. Scott, T. Azuhata, R. D. Williams, N. R. Wall, D. C. Altieri, and A. D. Sandler Induction and Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand-mediated Apoptosis in Renal Cell Carcinoma Cancer Res., June 1, 2002; 62(11): 3093 - 3099. [Abstract] [Full Text] [PDF]

				M. Fotin-Mleczek, F. Henkler, D. Samel, M. Reichwein, A. Hausser, I. Parmryd, P. Scheurich, J. A. Schmid, and H. Wajant Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8 J. Cell Sci., January 7, 2002; 115(13): 2757 - 2770. [Abstract] [Full Text] [PDF]

				S. Frese, T. Brunner, M. Gugger, A. Uduehi, and R. A. Schmid Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 168 - 174. [Abstract] [Full Text] [PDF]

				A. R. Jazirehi, C.-P. Ng, X.-H. Gan, G. Schiller, and B. Bonavida Adriamycin Sensitizes the Adriamycin-resistant 8226/Dox40 Human Multiple Myeloma Cells to Apo2L/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated (TRAIL) Apoptosis Clin. Cancer Res., December 1, 2001; 7(12): 3874 - 3883. [Abstract] [Full Text] [PDF]

				M. D. Southall, J. S. Isenberg, H. Nakshatri, Q. Yi, Y. Pei, D. F. Spandau, and J. B. Travers The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) alpha and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-kappa B-dependent Process J. Biol. Chem., November 30, 2001; 276(49): 45548 - 45554. [Abstract] [Full Text] [PDF]

				H. Higuchi, S. F. Bronk, Y. Takikawa, N. Werneburg, R. Takimoto, W. El-Deiry, and G. J. Gores The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis J. Biol. Chem., October 12, 2001; 276(42): 38610 - 38618. [Abstract] [Full Text] [PDF]

				A. E. Tollefson, K. Toth, K. Doronin, M. Kuppuswamy, O. A. Doronina, D. L. Lichtenstein, T. W. Hermiston, C. A. Smith, and W. S. M. Wold Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus Proteins J. Virol., October 1, 2001; 75(19): 8875 - 8887. [Abstract] [Full Text] [PDF]

				S. Kagawa, C. He, J. Gu, P. Koch, S.-J. Rha, J. A. Roth, S. A. Curley, L. C. Stephens, and B. Fang Antitumor Activity and Bystander Effects of the Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Gene Cancer Res., April 1, 2001; 61(8): 3330 - 3338. [Abstract] [Full Text]

				N. Droin, F. Bichat, C. Rebe, A. Wotawa, O. Sordet, A. Hammann, R. Bertrand, and E. Solary Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells Blood, March 15, 2001; 97(6): 1835 - 1844. [Abstract] [Full Text] [PDF]

				Y. Miura, N. Misawa, N. Maeda, Y. Inagaki, Y. Tanaka, M. Ito, N. Kayagaki, N. Yamamoto, H. Yagita, H. Mizusawa, et al. Critical Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) to Apoptosis of Human Cd4+T Cells in HIV-1-Infected Hu-Pbl-Nod-Scid Mice J. Exp. Med., March 5, 2001; 193(5): 651 - 660. [Abstract] [Full Text] [PDF]

				C. Hao, F. Beguinot, G. Condorelli, A. Trencia, E. G. Van Meir, V. W. Yong, I. F. Parney, W. H. Roa, and K. C. Petruk Induction and Intracellular Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Mediated Apotosis in Human Malignant Glioma Cells Cancer Res., February 1, 2001; 61(3): 1162 - 1170. [Abstract] [Full Text]

				A. Eggert, M. A. Grotzer, T. J. Zuzak, B. R. Wiewrodt, R. Ho, N. Ikegaki, and G. M. Brodeur Resistance to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Neuroblastoma Cells Correlates with a Loss of Caspase-8 Expression Cancer Res., February 1, 2001; 61(4): 1314 - 1319. [Abstract] [Full Text]

				R. Nimmanapalli, M. Porosnicu, D. Nguyen, E. Worthington, E. O’Bryan, C. Perkins, and K. Bhalla Cotreatment with STI-571 Enhances Tumor Necrosis Factor {{alpha}}-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells Clin. Cancer Res., February 1, 2001; 7(2): 350 - 357. [Abstract] [Full Text]

				R. Nimmanapalli, C. L. Perkins, M. Orlando, E. O’Bryan, D. Nguyen, and K. N. Bhalla Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels Cancer Res., January 1, 2001; 61(2): 759 - 763. [Abstract] [Full Text]

				W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al. Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617. [Abstract] [Full Text]

				J. Wen, N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington, and K. Bhalla Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells Blood, December 1, 2000; 96(12): 3900 - 3906. [Abstract] [Full Text] [PDF]

				M. Leverkus, H. Walczak, A. McLellan, H.-W. Fries, G. Terbeck, E.-B. Brocker, and E. Kampgen Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis Blood, October 1, 2000; 96(7): 2628 - 2631. [Abstract] [Full Text] [PDF]

				T. S. Griffith, R. D. Anderson, B. L. Davidson, R. D. Williams, and T. L. Ratliff Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis J. Immunol., September 1, 2000; 165(5): 2886 - 2894. [Abstract] [Full Text] [PDF]

				H. Wajant, E. Haas, R. Schwenzer, F. Muhlenbeck, S. Kreuz, G. Schubert, M. Grell, C. Smith, and P. Scheurich Inhibition of Death Receptor-mediated Gene Induction by a Cycloheximide-sensitive Factor Occurs at the Level of or Upstream of Fas-associated Death Domain Protein (FADD) J. Biol. Chem., August 4, 2000; 275(32): 24357 - 24366. [Abstract] [Full Text] [PDF]

				A. Nesterov, X. Lu, M. Johnson, G. J. Miller, Y. Ivashchenko, and A. S. Kraft Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis J. Biol. Chem., March 30, 2001; 276(14): 10767 - 10774. [Abstract] [Full Text] [PDF]

				D. Bernard, B. Quatannens, B. Vandenbunder, and C. Abbadie Rel/NF-kappa B Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1 J. Biol. Chem., July 13, 2001; 276(29): 27322 - 27328. [Abstract] [Full Text] [PDF]

				T. F. Burns and W. S. El-Deiry Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach J. Biol. Chem., October 5, 2001; 276(41): 37879 - 37886. [Abstract] [Full Text] [PDF]

				N. Harper, S. N. Farrow, A. Kaptein, G. M. Cohen, and M. MacFarlane Modulation of Tumor Necrosis Factor Apoptosis-inducing Ligand- induced NF-kappa B Activation by Inhibition of Apical Caspases J. Biol. Chem., September 7, 2001; 276(37): 34743 - 34752. [Abstract] [Full Text] [PDF]

				A. K. Simon, O. Williams, J. Mongkolsapaya, B. Jin, X. N. Xu, H. Walczak, and G. R. Screaton Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes PNAS, April 24, 2001; 98(9): 5158 - 5163. [Abstract] [Full Text] [PDF]